Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On September 16, 2008, the Board of Directors (the "Board") of Nanosphere, Inc. (the "Company") appointed Lorin Jeffry (Jeff) Randall to the Board. Mr. Randall was also appointed Chairman of the Board's Audit Committee effective immediately. In connection with Mr. Randall's appointment to the Board, Mr. Randall was awarded options to purchase 45,000 shares of the Company's common stock.

From 2004 to 2006, Mr. Randall was senior vice president-chief financial officer of Eximias Pharmaceutical Corporation, a development stage provider of oncology therapeutics. From 2002-2004, Mr. Randall held the same position at i-STAT Corporation, a manufacturer of medical diagnostic devices, which was acquired by Abbott Laboratories in 2004. His career also included senior management positions at CFM Technologies, a semiconductor manufacturing equipment company; Greenwich Pharmaceutical Corporation, a development stage provider of immune system disease therapeutics; and Surgilase, a provider of surgical lasers to hospitals and clinics. Mr. Randall received a B.S. in accounting from The Pennsylvania State University and an M.B.A. from Northeastern University.

There is no arrangement or understanding between Mr. Randall and any other persons pursuant to which Mr. Randall was selected as a director. There have been no transactions with the Company that exceed $120,000 in which Mr. Randall had a direct or indirect interest, per Item 404(a) of Regulation S-K.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits

Exhibit Number Description
99.1 Press Release of Nanosphere, Inc., dated September 18, 2008

---